Tonix Pharmaceuticals Holding Corp. (TNXP)
TNXP moved a median of -0.32% 30 minutes after news, and -1.63% by the close. How TNXP actually reacts to news — the realized, point-in-time move the market made, measured across 524 labeled events over the last three years with zero look-ahead.
TNXP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.13% | 44% | 521 |
| 30-min | -0.32% | 46% | 522 |
| 60-min | -1.12% | 40% | 522 |
| to close | -1.63% | 39% | 518 |
| Middle 50% of TNXP reactions | -3.09% to +2.10% |
|---|---|
| Median reaction (30-min) | -0.32% |
| Measured reactions | 524 |
Half of all Tonix Pharmaceuticals Holding Corp. news events land between -3.09% and +2.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TNXP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TNXP's baseline. Nothing else.
Recent TNXP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Tonix Pharmaceuticals For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | -8.50% | |
| Form 8-K Tonix Pharmaceuticals For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +1.55% | -3.11% | |
| Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® | Press release | GlobeNewswire | +1.55% | -3.11% | |
| Form 8-K Tonix Pharmaceuticals For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.94% | +0.08% | |
| Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer | Press release | GlobeNewswire | -1.94% | +0.08% | |
| Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference | Press release | GlobeNewswire | -1.07% | -4.43% | |
| Form 8-K Tonix Pharmaceuticals For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +1.81% | +0.47% | |
| Form 10-Q Tonix Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.16% | — | |
| Form 8-K Tonix Pharmaceuticals For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +5.16% | — | |
| Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights | Press release | GlobeNewswire | — | — | |
| Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.30% | +0.63% | |
| Form 8-K Tonix Pharmaceuticals For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +0.05% | +5.49% | |
| Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. | Press release | GlobeNewswire | +0.05% | +5.49% | |
| Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 | Press release | GlobeNewswire | +1.50% | +3.80% | |
| Form 8-K Tonix Pharmaceuticals For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | -6.94% | |
| Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models | Press release | GlobeNewswire | +1.07% | +3.94% | |
| Form 8-K Tonix Pharmaceuticals For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -1.76% | -6.43% | |
| Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA® | Press release | GlobeNewswire | -1.76% | -6.43% | |
| Form S-8 Tonix Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +1.82% | -2.30% | |
| Form 8-K Tonix Pharmaceuticals For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -1.70% | |
| Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) | Press release | GlobeNewswire | -0.46% | -1.70% | |
| Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 | Press release | GlobeNewswire | -2.27% | -3.18% | |
| Form 8-K Tonix Pharmaceuticals For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +6.15% | +1.47% | |
| Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives | Press release | GlobeNewswire | +6.15% | +1.47% | |
| Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting | Press release | GlobeNewswire | +0.23% | -2.38% | |
| Form 8-K Tonix Pharmaceuticals For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | -5.08% | |
| Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology | Press release | GlobeNewswire | -0.55% | -5.08% | |
| Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting | Press release | GlobeNewswire | -0.04% | -1.54% | |
| Form 8-K Tonix Pharmaceuticals For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | +14.81% | |
| Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026 | Press release | GlobeNewswire | +0.58% | +2.55% | |
| Tonix Pharmaceuticals to Participate in Two Investor Conferences in May | Press release | GlobeNewswire | -0.79% | +4.37% | |
| Form 10-Q Tonix Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.72% | +5.56% | |
| Form 8-K Tonix Pharmaceuticals For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +5.72% | +5.56% | |
| Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights | Press release | GlobeNewswire | +5.72% | +5.56% | |
| Form 8-K Tonix Pharmaceuticals For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.32% | +3.45% | |
| Form 8-K Tonix Pharmaceuticals For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +3.41% | +4.93% | |
| Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients | Press release | GlobeNewswire | +3.41% | +4.93% | |
| Form 8-K Tonix Pharmaceuticals For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +4.24% | -2.98% | |
| Form 8-K Tonix Pharmaceuticals For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -1.59% | -1.27% | |
| Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at | Press release | GlobeNewswire | -1.59% | -1.27% | |
| Form 8-K Tonix Pharmaceuticals For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | -4.80% | |
| Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 | Press release | GlobeNewswire | +0.45% | -4.80% | |
| Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development | Press release | GlobeNewswire | +3.71% | +7.42% | |
| Form 8-K Tonix Pharmaceuticals For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | +12.80% | |
| Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 | Press release | GlobeNewswire | +1.48% | +12.80% | |
| Form DEF 14A Tonix Pharmaceuticals For: May 07 | SEC filing · Form DEF | SEC EDGAR | -0.94% | -5.28% | |
| Form 8-K Tonix Pharmaceuticals For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | -3.85% | |
| Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain | Press release | GlobeNewswire | +1.33% | -3.85% | |
| Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 | Press release | GlobeNewswire | +1.14% | -3.16% | |
| Form PRE 14A Tonix Pharmaceuticals For: May 07 | SEC filing · Form PRE | SEC EDGAR | +3.48% | +6.49% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TNXP section they belong to.
Where else TNXP is measured.
TNXP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
| Quest Diagnostics Incorporated (DGX) | 524 | +0.03% | 51% |
| STAAR Surgical Company (STAA) | 522 | -0.21% | 44% |
| Surface Oncology, Inc. (SURF) | 521 | -0.69% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tonix Pharmaceuticals Holding Corp.'s median reaction calculated?
Every labeled TNXP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 524 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of TNXP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TNXP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.